



## **Mickey Ramchandani joins Amalgent Therapeutics as Vice President of Corporate Development**

Chapel Hill, NC July 29, 2021: Amalgent Therapeutics today announced a key addition to the management team with the appointment of Mickey Ramchandani as Vice President of Corporate Development.

“Mickey joins Amalgent at a pivotal time as we identify strategic partners to develop our potentially lifesaving efforts in acute pain management,” said Christopher B. Kelly, CEO of Amalgent. “I am especially pleased to be working with Mickey again, as I have known and valued his strategic perspective and counsel in the past. His broad and deep background in healthcare financing, partnering and execution lines up ideally with our current stage and strategy.”

Mickey has more than 25 years of strategy, corporate development and commercialization demonstrated successes in the pharmaceutical and medical technology industries. Most recently, Mickey was Founder and CEO of Global Lyme Diagnostics (GLD) where he successfully raised an oversubscribed Serie A/B financing.

Prior to GLD Mickey held roles of increasing responsibility with TranS1 (Baxano Surgical) starting as VP of Corporate Development & Strategy and later adding the General Manager role leading all non-US commercialization. Mickey has also held roles as Director of Licensing for pharmaceutical venture Kowa, and Director of New Business as well as Senior Marketing Manager at Baxter International. Mickey started his career in drug discovery research at Pfizer, Inc.

Mr. Ramchandani holds an MBA degree from UNC’s Kenan-Flagler Business School, an MS in Organic Chemistry from East Carolina University, and a BS in Chemistry from Campbell University.

### **About Amalgent Therapeutics:**

Amalgent is a clinical-stage pain management company that is developing an oral combination therapeutic for the US market. The Company’s fixed-dose combinations have a superior product profile to therapeutics on the market today.

### **Contact:**

Christopher B. Kelly  
Chief Executive Officer  
Amalgent Therapeutics  
<http://www.amalgent.com>  
[email](mailto:chris.kelly@amalgent.com) chris.kelly@amalgent.com  
Phone 1.919.225.9022